Skip to content

US · IBRX · BIOTECHNOLOGY

ImmunityBio, Inc. (IBRX) intrinsic value and stock valuation

$6.02as of 2026-11-21 · Mkt cap 8B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ImmunityBio, Inc. DCF and intrinsic value

InvestorsCraft values IBRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IBRX’s statements →

ImmunityBio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 immunitybio.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$113.3M+185.2% 5y CAGRd
20132025
Net income
-$-351.4M
20132025
Free cash flow
-$-308.78M
20132025
Total equity
-$-499.57M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$113.3M$14.7M$620K$240K$930K
Operating income-$-256.03M-$-344.18M-$-362.25M-$-351.3M-$-330.28M
Net income-$-351.4M-$-413.56M-$-583.2M-$-416.57M-$-346.79M
EPSd-$-382.01K-$-590.43K-$-1.15M-$-1.04M-$-890.96K
Operating cash flow-$-304.94M-$-391.24M-$-366.76M-$-337.51M-$-274.42M
Capital expenditure-$-3.85M-$-6.89M-$-30.58M-$-78.16M-$-33.56M
Free cash flow-$-308.78M-$-398.12M-$-397.34M-$-415.67M-$-307.98M
Total assets$501.9M$382.9M$504.5M$362.4M$468.9M
Total debt$878.1M$504.2M$726.7M$723.8M$645.7M
Net debt$789.8M$360.7M$461.3M$619.1M$464.6M
Total equity-$-499.57M-$-488.13M-$-585.94M-$-449.82M-$-243.91M
Cash and short-term investments$242.8M$149.8M$266.5M$107.2M$317.1M
Income statement
20252024202320222021
Revenue$113.3M$14.7M$620K$240K$930K
Cost of revenue$750K$0.00$0.00$0.00$0.00
Gross profit$112.5M$14.7M$620K$240K$930K
Research and development expenses$207.9M$190.1M$232.4M$248.2M$196M
Selling, general and administrative expenses$147.2M$168.8M$129.6M$102.7M$135.3M
Other expenses$13.5M$0.00$890K$680K$0.00
Operating expenses$368.6M$358.9M$362.9M$351.5M$331.2M
Cost and expenses$369.3M$358.9M$362.9M$351.5M$331.2M
Interest income$6.7M$2.4M$860K$2.71M$840K
Interest expense$112.5M$131.7M$86.7M$47.2M$14.9M
Depreciation and amortization$15.5M$17.6M$18.5M$18.3M$14.2M
Ebitda-$-223.56M-$-264.43M-$-478.66M-$-351.88M-$-320.75M
Operating income-$-256.03M-$-344.18M-$-362.25M-$-351.3M-$-330.28M
Total other income/expenses, net-$-95.58M-$-69.46M-$-221.64M-$-65.99M-$-19.56M
Income before tax-$-351.61M-$-413.64M-$-583.89M-$-417.29M-$-349.84M
Income tax expense-$-140K$0.00-$-40K$30K$10K
Net income-$-351.4M-$-413.56M-$-583.2M-$-416.57M-$-346.79M
Weighted average shares outstanding$919.9M$697.3M$508.6M$399.9M$389.2M
Weighted average diluted shares outstanding$919.9M$700.4M$508.6M$399.9M$389.2M
Balance sheet
20252024202320222021
Cash and short-term investments$242.8M$149.8M$266.5M$107.2M$317.1M
Net receivables$42.6M$2.65M$3.17M$1.89M$1.33M
Inventory$910K$8.27M$0.00$0.00$0.00
Total current assets$314.9M$184.6M$294.1M$140.6M$334.4M
Property, plant and equipment, net$147.5M$170.5M$182.7M$189.5M$119.2M
Goodwill and intangible assets$14M$15.9M$17.1M$20M$1.42M
Long-term investments$10.5M$700K$890K$840K$7.6M
Total non-current assets$187M$198.4M$210.4M$221.8M$134.6M
Total assets$501.9M$382.9M$504.5M$362.4M$468.9M
Accounts payable$6.98M$6.72M$9.2M$21M$11.4M
Short-term debt$9.29M$7.47M$5.24M$434.6M$302.3M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$61.8M$54.9M$58.3M$500.9M$369M
Long-term debt$868.8M$496.7M$721.5M$289.2M$343.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$939.7M$816.1M$1.03B$311.3M$343.8M
Capital lease obligations$33.7M$42.3M$45.2M$50.6M$40.1M
Total liabilities$1B$871.1M$1.09B$812.2M$712.8M
Common stock$100K$90K$70K$40K$40K
Retained earnings-$-3.73B-$-3.38B-$-2.96B-$-2.38B-$-1.96B
Accumulated other comprehensive income (loss)$29M$1.2M$10K$180K$0.00
Total equity-$-499.57M-$-488.13M-$-585.94M-$-449.82M-$-243.91M
Total investments$165M$7.08M$1.9M$3.38M$143.6M
Total debt$878.1M$504.2M$726.7M$723.8M$645.7M
Net debt$789.8M$360.7M$461.3M$619.1M$464.6M
Cash flow statement
20252024202320222021
Net income-$-351.47M-$-413.64M-$-583.85M-$-416.57M-$-346.79M
Depreciation and amortization$15.5M$17.6M$18.5M$34.5M$14.3M
Stock-based compensation$36.8M$34.4M$49.2M$40.2M$57.2M
Change in working capital-$-54.33M-$-19.42M$3.83M-$-16M-$-15.39M
Accounts receivable-$-40.21M-$-2.36M$0.00$0.00$0.00
Inventory-$-6.33M-$-8.27M$0.00$0.00$0.00
Accounts payable-$-190K-$-3.17M-$-6.48M$0.00$0.00
Net cash provided by operating activities-$-304.94M-$-391.24M-$-366.76M-$-337.51M-$-274.42M
Investments in property, plant and equipment-$-4.25M-$-6.89M-$-30.58M-$-78.16M-$-33.56M
Acquisitions, net$0.00-$-1M$0.00$0.00$0.00
Net cash used for investing activities-$-149.8M-$-12.25M-$-30.47M$27.3M-$-84.89M
Common stock issued$400.8M$111.4M$110.4M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00-$-620K-$-4.06M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$400.2M$281.6M$558.3M$233.6M$505.4M
Net change in cash-$-54.48M-$-121.88M$160.8M-$-76.31M$146.2M
Cash at end of period$89.4M$143.9M$265.8M$105M$181.3M
Operating cash flow-$-304.94M-$-391.24M-$-366.76M-$-337.51M-$-274.42M
Capital expenditure-$-3.85M-$-6.89M-$-30.58M-$-78.16M-$-33.56M
Free cash flow-$-308.78M-$-398.12M-$-397.34M-$-415.67M-$-307.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ImmunityBio, Inc.

        ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

        CEO
        Richard Gerald Adcock
        Employees
        691
        Beta
        0.13

        Explore

        Frequently asked questions

        What is the intrinsic value of ImmunityBio, Inc. (IBRX)?

        ImmunityBio, Inc. (IBRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IBRX undervalued?

        IBRX trades at a price of $6.02 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.